ArticleBMC pharmacology & toxicology2026
Network toxicology and bioinformatics reveal potential molecular links between cadmium exposure and pancreatic cancer.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnvironmental cadmium (Cd) pollution poses a severe threat to human health due to its strong bioaccumulation and high carcinogenicity. Although Cd exposure has been linked to various cancers, its specific role in pancreatic cancer (PC) remains unclear. This study aimed to explore the molecular mechanisms underlying Cd-associated PC and identify potential diagnostic and therapeutic targets.
methodsTranscriptomic data of PC were obtained from the GEO database to screen differentially expressed genes (DEGs), which were then intersected with Cd-related genes retrieved from the Comparative Toxicogenomics Database (CTD). Functional enrichment analyses, including GO and KEGG, were conducted to identify key biological processes and pathways. Multiple machine learning algorithms were used to construct a diagnostic model and identify hub genes. Furthermore, molecular docking and molecular dynamics simulations were performed to evaluate drug-target interactions, and in vitro experiments were used to validate the effects of Cd exposure on PC cell proliferation and invasiveness.
resultsA total of five key genes-FN1, COL5A1, AHR, COL3A1, and TIMP1-were identified as core regulators of Cd-associated PC. Functional analyses indicated that Cd primarily affects the extracellular matrix (ECM) metabolic and collagen remodeling pathways. Experimental results confirmed that Cd exposure significantly enhanced the proliferation and invasiveness of PC cells. Molecular docking and dynamics simulations revealed that the EGFR inhibitor dacomitinib exhibited favorable predicted binding affinity to FN1, suggesting its potential as a therapeutic agent.
conclusionsThis study reveals that Cd may promote the malignant progression of PC by regulating ECM remodeling through key genes such as FN1. Dacomitinib shows promise as an FN1-associated therapy, offering new insights for the precise prevention and treatment of Cd-associated PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.